National Jewish Health
- Type
- Teaching hospital
- Where
- Denver, CO
- Medicare CCN
- 060107
- Received
- $6,158,214 in 548 records, 2025 ($3,998,937 general, $2,159,276 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: National Jewish Health Fuzzy (name and state)
- Business registration: National Jewish Health Fuzzy (name and state)
- Business registration: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Business registration: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Business registration: National Jewish Health Company Fuzzy (name and state)
- Business registration: NATIONAL JEWISH HEALTH, INC. Fuzzy (name and state)
- Nonprofit contractor: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Plan sponsor: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Federal award recipient: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Nonprofit: NATIONAL JEWISH HEALTH Fuzzy (name and state)
- Patent assignee: National Jewish Health Fuzzy (name and state)
- Trademark owner: National Jewish Health Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 115 | $3,998,937 |
| 2025 | Research payment | 433 | $2,159,276 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Grant | 17 | $3,103,297 |
| Research payment | 433 | $2,159,276 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 42 | $626,984 |
| Space rental or facility fees (teaching hospital only) | 19 | $91,375 |
| Charitable Contribution | 3 | $61,500 |
| Gift | 2 | $50,000 |
| Royalty or License | 24 | $43,352 |
| Consulting Fee | 3 | $10,851 |
| Education | 3 | $10,500 |
| Debt forgiveness | 2 | $1,078 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $4,861 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2025 |
| 2025-12-31 | Electromed, Inc. | $4,000 | Consulting Fee | Cash or cash equivalent | SMARTVEST Device, HFCWO | 2025 | |
| 2025-12-31 | Takeda Pharmaceuticals U.S.A., Inc. | $135 | Research payment | Cash or cash equivalent | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | 2025 | |
| 2025-12-29 | Paratek Pharmaceuticals, Inc. | $29,673 | Research payment | Cash or cash equivalent | NUZYRA Drug, ANTIBIOTIC | 2025 | |
| 2025-12-24 | United Therapeutics Corporation | $3,939 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-24 | ARGENX US, INC. | $2,291 | Research payment | Cash or cash equivalent | 2025 | ||
| 2025-12-24 | United Therapeutics Corporation | $886 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $886 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $770 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | $78,986 | Research payment | Cash or cash equivalent | OFEV Drug, RESPIRATORY | Evaluation of short-term change in quantitative CT as a marker of progressive pulmonary fibrosis | 2025 |
| 2025-12-19 | Life Technologies Corporation | $15,140 | Royalty or License (19 payments) | Cash or cash equivalent | 2025 | ||
| 2025-12-19 | Apellis Pharmaceuticals, Inc. | $11,900 | Research payment | Cash or cash equivalent | Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic | 2025 | |
| 2025-12-19 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-19 | Apellis Pharmaceuticals, Inc. | $5,000 | Research payment | Cash or cash equivalent | Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic | 2025 | |
| 2025-12-19 | Takeda Pharmaceuticals U.S.A., Inc. | $2,506 | Research payment | Cash or cash equivalent | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB | 2025 | |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $988 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $530 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $499 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $475 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $399 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $186 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $160 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $140 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $123 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $100 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $68 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $65 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $61 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $57 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $54 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-18 | Regeneron Pharmaceuticals, Inc. | $50 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-12-17 | GENZYME CORPORATION | $8,829 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | A Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie | 2025 |
| 2025-12-17 | United Therapeutics Corporation | $2,525 | Research payment | Cash or cash equivalent | A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION | 2025 | |
| 2025-12-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | $470 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | $36 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | $2 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-12-16 | AstraZeneca Pharmaceuticals LP | $33,000 | Charitable Contribution | Cash or cash equivalent | 2025 | ||
| 2025-12-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | $32,301 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-12-15 | United Therapeutics Corporation | $3,124 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 | |
| 2025-12-10 | ARGENX US, INC. | $1,806 | Research payment | Cash or cash equivalent | 2025 | ||
| 2025-12-10 | United Therapeutics Corporation | $1,732 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-10 | United Therapeutics Corporation | $1,000 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-12-10 | United Therapeutics Corporation | $399 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-12-09 | AstraZeneca Pharmaceuticals LP | $349,337 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $185,960 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-09 | AstraZeneca Pharmaceuticals LP | $25,000 | Charitable Contribution | Cash or cash equivalent | 2025 | ||
| 2025-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,999 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-12-04 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Research payment | Cash or cash equivalent | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | 2025 | |
| 2025-12-04 | NS Pharma, Inc. | $835 | Research payment | Cash or cash equivalent | VILTEPSO Drug, PEDIATRIC NEUROLOGY | Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | 2025 |
| 2025-12-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,336 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-12-02 | Insmed, Inc. | $390,810 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-01 | Janssen Research & Development, LLC | $6,299 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2025 | |
| 2025-12-01 | Boehringer Ingelheim International GmbH | $34 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-12-01 | Boehringer Ingelheim International GmbH | $3 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-11-28 | Apellis Pharmaceuticals, Inc. | $1,477 | Research payment | Cash or cash equivalent | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | 2025 | |
| 2025-11-28 | Apellis Pharmaceuticals, Inc. | $725 | Research payment | Cash or cash equivalent | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | 2025 | |
| 2025-11-26 | United Therapeutics Corporation | $3,172 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-11-26 | United Therapeutics Corporation | $1,819 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-11-26 | United Therapeutics Corporation | $793 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-11-26 | United Therapeutics Corporation | $793 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-11-24 | NS Pharma, Inc. | $2,366 | Research payment | Cash or cash equivalent | VILTEPSO Drug, PEDIATRIC NEUROLOGY | Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | 2025 |
| 2025-11-24 | NS Pharma, Inc. | $1,772 | Research payment | Cash or cash equivalent | VILTEPSO Drug, PEDIATRIC NEUROLOGY | Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | 2025 |
| 2025-11-20 | United Therapeutics Corporation | $2,949 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 | |
| 2025-11-20 | Genentech, Inc. | $890 | Research payment | Cash or cash equivalent | Tecentriq Biological, BioOncology | Neoadjuvant NSCLC | 2025 |
| 2025-11-19 | GENZYME CORPORATION | $5,096 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | A Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie | 2025 |
| 2025-11-19 | United Therapeutics Corporation | $723 | Research payment | Cash or cash equivalent | A STUDY EVALUATING THE LONG-TERM EFFICACY AND SAFETY OF RALINEPAG IN SUBJECTS WITH PAH VIA AN OPEN-LABEL EXTENSION | 2025 | |
| 2025-11-19 | Becton, Dickinson and Company | $113 | Royalty or License | Cash or cash equivalent | 2025 | ||
| 2025-11-19 | Becton, Dickinson and Company | $68 | Royalty or License | Cash or cash equivalent | 2025 | ||
| 2025-11-19 | Boehringer Ingelheim International GmbH | $43 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-11-19 | Becton, Dickinson and Company | $41 | Royalty or License | Cash or cash equivalent | 2025 | ||
| 2025-11-19 | Boehringer Ingelheim International GmbH | $23 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-11-19 | Becton, Dickinson and Company | $11 | Royalty or License | Cash or cash equivalent | 2025 | ||
| 2025-11-14 | Genentech USA, Inc. | $3,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Xolair Biological, Immunology | 2025 | |
| 2025-11-14 | Takeda Pharmaceuticals U.S.A., Inc. | $2,333 | Research payment | Cash or cash equivalent | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB | 2025 | |
| 2025-11-12 | United Therapeutics Corporation | $4,970 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-11-12 | United Therapeutics Corporation | $2,612 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-11-12 | United Therapeutics Corporation | $2,612 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-11-07 | Genentech, Inc. | $82,384 | Research payment | Cash or cash equivalent | Xolair Biological, Immunology | Effect of Omalizumab in the Skin of Food Allergy Patients | 2025 |
| 2025-11-07 | Verona Pharma, Inc. | $6,327 | Research payment | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | Verona | 2025 |
| 2025-11-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-11-01 | Takeda Pharmaceuticals U.S.A., Inc. | $135 | Research payment | Cash or cash equivalent | LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) | 2025 | |
| 2025-11-01 | Boehringer Ingelheim International GmbH | $34 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-11-01 | Boehringer Ingelheim International GmbH | $3 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-10-30 | Janssen Research & Development, LLC | $399 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2025 | |
| 2025-10-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-10-29 | Takeda Pharmaceuticals U.S.A., Inc. | $2,333 | Research payment | Cash or cash equivalent | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB | 2025 | |
| 2025-10-28 | Beckman Coulter, Inc. | $10,000 | Royalty or License | Cash or cash equivalent | 2025 | ||
| 2025-10-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,181 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | $146 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | $99 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | $73 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | $23 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | $3 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | $3 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | $0 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-10-24 | GENZYME CORPORATION | $5,440 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | A Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie | 2025 |
| 2025-10-24 | Apellis Pharmaceuticals, Inc. | $450 | Research payment | Cash or cash equivalent | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | 2025 | |
| 2025-10-23 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000 | Research payment | Cash or cash equivalent | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB | 2025 | |
| 2025-10-22 | United Therapeutics Corporation | $2,839 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-10-16 | Alexion Pharmaceuticals, Inc. | $21,504 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-10-16 | Alexion Pharmaceuticals, Inc. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-10-16 | United Therapeutics Corporation | $1,077 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 | |
| 2025-10-10 | Apellis Pharmaceuticals, Inc. | $900 | Research payment | Cash or cash equivalent | A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | 2025 | |
| 2025-10-09 | Alexion Pharmaceuticals, Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-10-09 | Takeda Pharmaceuticals U.S.A., Inc. | $2,333 | Research payment | Cash or cash equivalent | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB | 2025 | |
| 2025-10-09 | GENZYME CORPORATION | $524 | Research payment | Cash or cash equivalent | NEXVIAZYME Biological, Genetic Disease | An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ | 2025 |
| 2025-10-08 | GENZYME CORPORATION | $33,679 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | A Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie | 2025 |
| 2025-10-08 | GENZYME CORPORATION | $32,462 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S | 2025 |
| 2025-10-08 | VERTEX PHARMACEUTICALS INCORPORATED | $17,645 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-10-08 | Paratek Pharmaceuticals, Inc. | $14,593 | Research payment | Cash or cash equivalent | NUZYRA Drug, ANTIBIOTIC | 2025 | |
| 2025-10-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,807 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-10-03 | Apellis Pharmaceuticals, Inc. | $4,000 | Research payment | Cash or cash equivalent | 2025 | ||
| 2025-10-03 | GENZYME CORPORATION | $300 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | A Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie | 2025 |
| 2025-10-02 | Regeneron Pharmaceuticals, Inc. | $34,998 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | Predictors and characteristics of asthma remission in individuals with moderate to severe asthma receiving dupilumab. | 2025 |
| 2025-10-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,300 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-10-01 | ARGENX US, INC. | $1,486 | Research payment | Cash or cash equivalent | 2025 | ||
| 2025-10-01 | Boehringer Ingelheim International GmbH | $34 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-10-01 | Boehringer Ingelheim International GmbH | $3 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-09-30 | E.R. Squibb & Sons, L.L.C. | $88 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizum | 2025 | |
| 2025-09-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,439 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | $146 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | $23 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-09-23 | Becton, Dickinson and Company | $3,000 | Royalty or License | Cash or cash equivalent | 2025 | ||
| 2025-09-22 | United Therapeutics Corporation | $3,364 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 | |
| 2025-09-18 | Takeda Pharmaceuticals U.S.A., Inc. | $2,333 | Research payment | Cash or cash equivalent | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB | 2025 | |
| 2025-09-17 | Regeneron Pharmaceuticals, Inc. | $27,732 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | Predictors and characteristics of asthma remission in individuals with moderate to severe asthma receiving dupilumab. | 2025 |
| 2025-09-17 | GENZYME CORPORATION | $600 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | A Two-year, Phase 4, Open-label, Single-arm Treatment Study to Evaluate the Long-term Effect of Dupilumab on Skin Barrie | 2025 |
| 2025-09-12 | GENZYME CORPORATION | $151 | Research payment | Cash or cash equivalent | NEXVIAZYME Biological, Genetic Disease | An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ | 2025 |
| 2025-09-11 | Alexion Pharmaceuticals, Inc. | $8,940 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-09-11 | Alexion Pharmaceuticals, Inc. | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-09-11 | GENZYME CORPORATION | $99 | Research payment | Cash or cash equivalent | NEXVIAZYME Biological, Genetic Disease | An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ | 2025 |
| 2025-09-10 | United Therapeutics Corporation | $3,000 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-09-10 | United Therapeutics Corporation | $2,639 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-09-10 | United Therapeutics Corporation | $1,819 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-09-10 | United Therapeutics Corporation | $1,578 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-09-10 | United Therapeutics Corporation | $799 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-09-10 | United Therapeutics Corporation | $533 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-09-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,300 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-09-04 | NS Pharma, Inc. | $2,926 | Research payment | Cash or cash equivalent | VILTEPSO Drug, PEDIATRIC NEUROLOGY | Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | 2025 |
| 2025-09-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,075 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-09-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $626 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-09-03 | CSL Behring | $3,600 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immun | 2025 |
| 2025-09-03 | CSL Behring | $3,200 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immun | 2025 |
| 2025-09-03 | CSL Behring | $500 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | Double-blind, Randomized, Placebo-controlled Phase 3 Study Evaluating Efficacy and Safety of IgPro20 (Subcutaneous Immun | 2025 |
| 2025-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $239,216 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,000 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,848 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | $34 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-09-01 | Boehringer Ingelheim International GmbH | $3 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-08-29 | Insmed, Inc. | $50,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-08-29 | Mannkind Corporation | $1,593 | Research payment | Cash or cash equivalent | ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION | 2025 | |
| 2025-08-29 | Apellis Pharmaceuticals, Inc. | $1,142 | Research payment | Cash or cash equivalent | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | 2025 | |
| 2025-08-29 | Apellis Pharmaceuticals, Inc. | $365 | Research payment | Cash or cash equivalent | Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | 2025 | |
| 2025-08-28 | Grifols USA, LLC | $2,000 | Education | Cash or cash equivalent | Prolastin-C Liquid Biological, Pulmonology | 2025 | |
| 2025-08-27 | Regeneron Healthcare Solutions, Inc. | $47,500 | Grant | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-27 | United Therapeutics Corporation | $1,819 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-08-27 | ARGENX US, INC. | $1,380 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolera | 2025 |
| 2025-08-26 | Boehringer Ingelheim Pharmaceuticals, Inc. | $38,850 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-08-26 | Boehringer Ingelheim International GmbH | $255 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-08-26 | Becton, Dickinson and Company | $159 | Royalty or License | Cash or cash equivalent | 2025 | ||
| 2025-08-26 | Becton, Dickinson and Company | $95 | Royalty or License | Cash or cash equivalent | 2025 | ||
| 2025-08-26 | Boehringer Ingelheim International GmbH | $65 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | $59 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | $58 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-08-26 | Becton, Dickinson and Company | $47 | Royalty or License | Cash or cash equivalent | 2025 | ||
| 2025-08-26 | Becton, Dickinson and Company | $38 | Royalty or License | Cash or cash equivalent | 2025 | ||
| 2025-08-26 | Becton, Dickinson and Company | $33 | Royalty or License | Cash or cash equivalent | Horizon Device, Reagents | 2025 | |
| 2025-08-26 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-08-26 | Boehringer Ingelheim International GmbH | $10 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-08-21 | Alexion Pharmaceuticals, Inc. | $5,145 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-08-21 | Takeda Pharmaceuticals U.S.A., Inc. | $2,333 | Research payment | Cash or cash equivalent | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB | 2025 | |
| 2025-08-21 | NS Pharma, Inc. | $1,772 | Research payment | Cash or cash equivalent | VILTEPSO Drug, PEDIATRIC NEUROLOGY | Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | 2025 |
| 2025-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,269 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-08-19 | NS Pharma, Inc. | $815 | Research payment | Cash or cash equivalent | VILTEPSO Drug, PEDIATRIC NEUROLOGY | Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | 2025 |
| 2025-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-08-14 | Alexion Pharmaceuticals, Inc. | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-08-13 | GENZYME CORPORATION | $3,732 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open-label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Pediatric Patients With Mod | 2025 |
| 2025-08-13 | GENZYME CORPORATION | $3,732 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Open Label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Patients With Moderate to S | 2025 |
| 2025-08-13 | United Therapeutics Corporation | $240 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2025 | |
| 2025-08-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-08-07 | Takeda Pharmaceuticals U.S.A., Inc. | $2,333 | Research payment | Cash or cash equivalent | MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERAB | 2025 | |
| 2025-08-06 | ARGENX US, INC. | $447 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolera | 2025 |
| 2025-08-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,000 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | $3,131 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-08-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $399 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | $362 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | $238 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks i | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | $34 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-08-01 | Boehringer Ingelheim International GmbH | $3 | Research payment | In-kind items and services | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-07-31 | Regeneron Pharmaceuticals, Inc. | $25,000 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-07-31 | Regeneron Pharmaceuticals, Inc. | $2,666 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
| 2025-07-31 | Regeneron Pharmaceuticals, Inc. | $2,500 | Research payment | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM | 2025 |
The latest 200 records of 548.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Denver, CO, county Denver County, CO, state Colorado; placed by its city name.
| Measure | Place (city or town) Denver, CO | County Denver County, CO | State Colorado |
|---|---|---|---|
| Population B01003 | 718,877 | 718,877 | 5,862,189 |
| Population, 2020 census P1 | 715,522 | 715,522 | 5,773,714 |
| Median age B01002 | 35.3 | 35.3 | 37.7 |
| Under 18 B01001 | 18.0% | 18.0% | 21.0% |
| 65 and over B01001 | 12.5% | 12.5% | 15.6% |
| Households B11001 | 335,428 | 335,428 | 2,374,218 |
| Foreign born B05002 | 14.5% | 14.5% | 9.8% |
| Median household income B19013 | $94,718 | $94,718 | $95,470 |
| Median family income B19113 | $124,743 | $124,743 | $119,139 |
| Per capita income B19301 | $64,163 | $64,163 | $52,636 |
| Poverty rate B17001 | 11.2% | 11.2% | 9.4% |
| Unemployment rate B23025 | 4.9% | 4.9% | 4.6% |
| Civilian labor force B23025 | 447,681 | 447,681 | 3,235,476 |
| Mean commute (minutes) B08013 | 24.9 | 24.9 | 25.2 |
| Bachelor's degree or higher B15003 | 56.5% | 56.5% | 45.7% |
| Housing units B25001 | 359,581 | 359,581 | 2,589,053 |
| Owner-occupied B25003 | 48.8% | 48.8% | 66.2% |
| Renters B25003 | 51.2% | 51.2% | 33.8% |
| Median home value B25077 | $616,000 | $616,000 | $539,400 |
| Median gross rent B25064 | $1,831 | $1,831 | $1,761 |
| White, not Hispanic B03002 | 54.0% | 54.0% | 64.8% |
| Black B03002 | 8.6% | 8.6% | 3.8% |
| Hispanic or Latino B03002 | 28.0% | 28.0% | 22.5% |
| Asian B03002 | 3.6% | 3.6% | 3.2% |
| American Indian and Alaska Native B03002 | 0.3% | 0.3% | 0.4% |
Economy now FRED unemployment 4.1% in Sep 2026 (3.8% a year earlier); per capita personal income $86,342 in 2025, up 34% in five years (+7.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Denver, CO.
Comments